Business
    Next Score View the next score

    Mass. Movers

    Bank reaffirms ‘neutral’ rating on Idenix

    Idenix aims to develop drugs to treat viral diseases.
    Associated Press/File 2012
    Idenix aims to develop drugs to treat viral diseases.

    Bank of America reaffirmed its “neutral” rating on shares of Cambridge-based Idenix Pharmaceuticals in a research note released Monday, according to Jags Report. The bank currently has a $7 price target, up from $6. Idenix announced a nonexclusive collaboration with Janssen Pharmaceuticals Inc. for “the clinical development of all-oral direct-acting antiviral HCV combination therapies” — in other words, drug combinations to treat infection with the hepatitis C virus.

    Advertisement